|
| Authors, references | No. of patients | Regimens | Toxicity | Followup | Results |
|
| Dreicer et al., [9] | 29 | Docetaxel | NUT | 23 m | 20 patients disease-free |
| Magi-Galluzzi et al., [10] | 28 | Docetaxel | NUT | 49.5 m | 43% biochemical-free |
| Febbo et al., [11] | 19 | Docetaxel | NUT (fatigue and taste disturbances) | n/a | >50% of PSA in 58% of patients, no pathological complete response |
| Chi et al., [12] | 64 | Docetaxel plus CAB | 4 withdrawals | 42.7 m | 2 pathological complete responses, 70% recurrence-free survival |
| Mellado et al., [13] | 57 | Docetaxel plus CAB | 10.1% of patients did not complete the therapy | 35 m | 6% pathological complete responses |
| Kim et al., [14] | 12 RP/22 RT | Docetaxel plus estramustine | 1 withdrawal | 24 m | >25% of PSA in 21/22 of patients, 45% progression-free survival |
| Hussain et al., [15] | 10 RP/11 RT | Docetaxel plus estramustine | 2 patients with grade 3 deep venous thrombosis, 1 patient with grade 4 neutropenia | n/a | Positive surgical margins in 3 patients |
| Prayer-Galetti et al., [16] | 21 | Docetaxel plus estramustine plus LHRH analogue | NUT | 53 m | 26% positive surgical margins, 58% organ-confined disease, 42% disease-free, 15% complete response, 80% partial response |
| Sella et al., [17] | 22 | Docetaxel plus estramustine plus CAB | NUT | 23.6 m | 54.5% disease-free survival |
| Narita et al., [18] | 18 | Docetaxel plus estramustine + CAB | No grade 3 or 4 toxicities | 18 m | 11% pathological complete response, 77.8% disease-free survival |
| Garzotto et al., [19] | 22 | Docetaxel plus mitoxantrone | Grade 4 leukopenia, neutropenia, hyperglycemia | 63 m | Recurrence-free survival after 2 y and 5 y was 65.5% and 49.8% |
| Womble et al., [20] | 22 | Docetaxel plus ketoconazole | 4 withdrawals, 16 patients with grade 3/4 toxicities | 18 m | 8/18 biochemical-free |
| Friedman et al., [21] | 15 | Docetaxel plus capecitabine | NUT | n/a | No pathological complete responses |
| Ross et al., [22] | 41 | Docetaxel plus bevacizumab | 3 withdrawals, 3 patients with grade 3 neutropenia | n/a | >50% of PSA in 22% of patients, no pathological complete responses |
| Shepard et al., [23] | 18 | Paclitaxel | 10 patients with grade 3 and 1 patient with grade 4 neutropenia | n/a | 95% PSA decrease, no pathological complete responses |
| Konety et al., [24] | 36 | Paclitaxel plus carboplatin plus estramustine plus CAB | Deep vein thrombosis in 22% of patients | 29 | 45% biochemical recurrence-free survival |
| Clark et al., [25] | 18 | Estramustine plus etoposide | 1 patient with grade 4 pulmonary embolism, 2 patients with grade 3 deep venous thrombosis | 14 | Rate of organ-confined disease, thromboembolism in 3 patients |
| Garcia et al., [26] | 28 | Thalidomide plus GM-CSF | NUT | 32 | 5/28 patients had recurrence |
| Pettaway et al., [27] | 33 | Doxorubicin plus ketoconazole plus estramustine plus vinblastine plus CAB | NUT | 13 | 17% positive surgical margins, 20/29 patients with no disease recurrence |
| Weight et al., [28] | 93 (control study) | Exisulind | NUT | n/a | No effects on biomarkers of cell death |
|
